Insulin glargine: An updated review of its use in the management of diabetes mellitus

Drugs

Volumn 63, Issue 16, 2003, Pages 1743-1778

  Dunn, Christopher J ^a   Plosker, Greg L ^a   Keating, Gillian M ^a   McKeage, Kate ^a   Scott, Lesley J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; INSULIN; INSULIN GLARGINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT;

BLOOD GLUCOSE MONITORING; CARBOXY TERMINAL SEQUENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; HUMAN; HYPOGLYCEMIA; INJECTION SITE; INSULIN DEPENDENT DIABETES MELLITUS; META ANALYSIS; MITOGENESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SKIN MANIFESTATION;

ADOLESCENT; ADULT; AGED; DIABETES MELLITUS; DRUG ADMINISTRATION SCHEDULE; GREAT BRITAIN; HUMANS; INJECTIONS, SUBCUTANEOUS; INSULIN; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME;

EID: 0041733061     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363160-00007     Document Type: Review

References (111)

1. International Diabetes Federation. Diabetes Prevalence [online]. Available from URL: http://www.idf.org [Accessed 2003 Apr 24]
2. American Diabetes Association. Basic Diabetes Information: Facts and Figures [online]. Available from URL: http://www.diabetes.org [Accessed 2003 Apr 24]
3. Mandrup-Poulsen T. Diabetes. BMJ 1998 Apr 18; 316: 1221-5
4. American Diabetes Association. Implications of the Diabetes Control and Complications Trial. Diabetes Care 2003; 26 Suppl. 1: S25-7
5. American Diabetes Association. Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care 2003; 26 Suppl. 1: S28-32
6. National Institute for Clinical Excellence. Guidance on the use of long-acting insulin analogues for the treatment of diabetes: insulin glargine. Technology Appraisal Guidance 2002 Dec, No. 53
7. Vajo Z, Fawcett J, Duckworth WC. Recombinant DNA technology in the treatment of diabetes: insulin analogs. Endocr Rev 2001 Oct; 22 (5): 706-17
8. McKeage K, Goa KL. Insulin glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus. Drugs 2001; 61 (11): 1599-624
9. Aventis Pharmaceuticals Inc. Lantus® (insulin glargine [rDNA origin] injection) prescribing information [online]. Available from URL: http://www.aventis.com [Accessed 2003 Apr 9]
10. Scholtz HE, van Niekerk N, Meyer BH, et al. An assessment of the variability in the pharmacodynamics (glucose lowering effect) of HOE901 compared to NPH and ultralente human insulins using the euglycaemic clamp technique [abstract no. 882]. Diabetologia 1999; 49 Suppl. 1: 999-1005
11. Ciaraldi TP, Carter L, Seipke G, et al. Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-I. J Clin Endocrinol Metab 2001 Dec; 86 (12): 5838-47
12. Berti L, Kellerer M, Bossenmaier B, et al. The long acting human insulin analog HOE 901: characteristics of insulin signalling in comparison to Asp(B10) and regular insulin. Horm Metab Res 1998; 30: 123-9
13. European Agency for the Evaluation of Medicinal Products. Insulin glargine: summary of product characteristics [online]. Available from URL: http: //www.emea.eu.int [Accessed 2003 Apr 9]
14. Kurtzhalas P, Schaffer L, Sorensen A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000; 49: 999-1005
15. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000 Dec; 49: 2142-8
16. Soon PC, Matthews DR, Rosskamp R, et al. 24h profile of action of biosynthetic long-acting insulin (HOE901) tested in normal volunteers by glucose clamp methodology [abstract no. 0621]. Diabetes 1997; 46 Suppl. 1: 161A
17. Heinemann L, Linkeschova T, Rave K, et al. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000 May; 23 (5): 644-9
18. Fanelli CG, Pampanelli S, Porcellati F, et al. Pharmacodynamics of subcutaneous injection of insulin glargine after the first as compared to seventh day of its once daily administration in patients with T1 DM [abstract no. 802]. Diabetologia 2002 Aug; 45 Suppl. 2: A258
19. Meyer BH, Scholtz HE, Pretorius SG, et al. A comparison of the pharmacodynamics (glucose lowering effect) of intravenous HOE901 and regular insulin using the euglycaemic clamp technique [abstract no. PII-34]. Clin Pharmacol Ther 2000; 67 (2): 123
20. Mudaliar S, Mohideen P, Deutsch R, et al. Intravenous glargine and regular insulin have similar effects on endogenous glucose output and peripheral activation/deactivation kinetic profiles. Diabetes Care 2002 Sep; 25 (9): 1597-602
21. King AB, Armstrong D. A comparison of basal insulin delivery: continuous subcutaneous insulin infusion versus glargine [letter]. Diabetes Care 2003 Apr; 26 (4): 1322
22. Dagogo-Jack S, Askari H, Lehner LL. Effect of glargine on glucose disposal and lipolysis in healthy and diabetic subjects [abstract no. 1737]. Diabetes 2000; 49 Suppl. 1: 213
23. Dagogo-Jack S, Askari H, Morrill B, et al. Physiological responses during hypoglycaemia induced by regular human insulin or a novel human analogue, insulin glargine. Diabetes, Obes Metab 2000; 2: 373-83
24. Sandow J, Seipke G. In vitro pharmacology studies with insulin glargine and human insulin: IGF-1 receptor binding and thymidine incorporation [abstract no. 1787-PO]. Diabetes 2001; 50 Suppl. 2: 429
25. Bähr M, Kolter T, Seipke G, et al. Growth promoting and metabolic activity of the human insulin analogue [GlyA21,ArgB31,ArgB32] insulin (HOE901) in muscle cells. Eur J Pharmacol 1997; 320: 259-65
26. Slawik M, Petersen KG. Effects of basal insulin treatment on IGF-I: glargine vs. NPH-insulin [abstract no. 1202-P]. Diabetes 2002; 51 Suppl. 2: A296
27. Stammberger I, Bube A, Durchfeld-Meyer B, et al. Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice. Int J Toxicol 2002 May-2002 30; 21 (3): 171-9
28. Seipke G, Berchthold H, Geisen K, et al. HOE901: a new insulin with prolonged action [abstract]. Eur J Endocrinol 1995; 132 Suppl. 1: 25
29. Vehkavaara S, Yki-Järvinen H. 3.5 Years of insulin therapy with insulin glargine at bedtime markedly improves in vivo endothelial function in type 2 diabetes [abstract no. 699-P]. Diabetes 2002; 51 Suppl. 2: A173
30. Bolli GB, Owens DR. Insulin glargine. Lancet 2000; 356: 443-5
31. Hofmann T, Horstmann G, Stammberger I. Evaluation of the reproductive toxicity and embryotoxicity of insulin glargine (LANTUS) in rats and rabbits. Int J Toxicol 2002; 21 (3): 181-9
32. 125I-labeled insulin glargine (HOE 901) in healthy men. Diabetes Care 2000 Jun; 23 (6): 813-9
33. Gerich J, Bolli G, Becker R, et al. Fluctuation of serum insulin levels following single and multiple dosing of insulin glargine [abstract]. Proceedings of the 63rd Annual Scientific Sessions of the American Diabetes Association; 2003 Jun 13-17; New Orleans, Louisiana
34. Luzio SD, Owens D, Evans M, et al. Comparison of the sc absorption of HOE 901 and NPH human insulin type 2 diabetic subjects [abstract no. 0480]. Diabetes 1999 May; 48 Suppl. 1: A111
35. Heise T, Bott S, Rave K, et al. No evidence for accumulation of insulin glargine (LANTUS): a multiple injection study in patients with type 1 diabetes. Diabet Med 2002 Jun; 19 (6): 490-5
36. Kuerzel GU, Shukla U, Scholtz HE, et al. Biotransformation of insulin glargine after subcutaneous injection in healthy subjects. Curr Med Res Opin 2003; 19 (1): 34-40
37. Sandow J, Seipke G, Kuerzel GU, et al. Pharmacokinetics and metabolism of insulin glargine [abstract no. P1-358]. 82nd Annual Meeting of the Endocrine Society; 2001 Jun 20-23; Denver, Colorado
38. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2003; 26 Suppl. 1: S33-50
39. Sacks DB, Bruns DE, Goldstein DE, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2002; 48: 436-72
40. Schoenle E. Insulin glargine (HOE 901) lowers fasting blood glucose in children with type 1 diabetes mellitus without increasing the risk of hypoglycaemia [abstract no. 883]. HOE 901/3033 Study Group. Diabetologia 1999; 42 Suppl. 1: A235
41. Hershon K, Blevins T, Donley D, et al. Lower fasting blood glucose (FBG) and less symptomatic hypoglycemia with QD insulin glargine (Lantus) compared to BID NPH in subjects with type 1 diabetes [abstract no. 466-P]. Diabetes 2001; 50 Suppl. 2: 116-7
42. Pieber TR, Eugene-Jolchine I, Derobert E, et al. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes mellitus. Diabetes Care 2000; 23: 157-62
43. Rosenstock J, Park G, Zimmerman J, et al. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. Diabetes Care 2000; 23: 1137-42
44. Raskin P, Klaff L, Bergenstal R, et al. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 2000; 23: 1666-71
45. Ratner RE, Hirsch IB, Neifing JL, et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 2000; 23: 639-43
46. Home P. A randomized, multicentre trial of insulin glargine versus NPH insulin in people with type 1 diabetes [abstract no. 800]. European Insulin Glargine Study Group. Diabetologia 2002 Aug; 45 Suppl. 2: A258
47. Standl E. Results of an international, multicentered, randomised 28-week study for the comparison of glargine insulin (HOE 901) and NPH insulin in the intensified treatment (ICT) of type 1 diabetes [abstract no. pFr107] [in German]. Exp Clin Endocrinol Diabetes 2000; 108 Suppl. 1: 159
48. Ashwell S, Amiel S, Bilous R, et al. Improvement in HbAlc with insulin glargine + insulin lispro in comparison with NPH insulin + unmodified human insulin in people with type 1 diabetes [abstract]. Proceedings of the 63rd Annual Scientific Sessions of the American Diabetes Association; 2003 Jun 13-17; New Orleans, Louisiana
49. Fulcher G, Yue D, Gilbert R, et al. Insulin glargine vs. NPH insulin in patients with type 1 diabetes: the effects of intensive insulin therapy on glycaemic control, hypoglycaemia and quality of life [abstract]. Diabetologia 2002 Aug; 45 Suppl. 2: A258
50. Porcellati F, Rossetti P, Fanelli CG, et al. Glargine vs NPH as basal insulin in intensive treatment of TIDM given lispro at meals: one year comparison [abstract no. 145]. Diabetologia 2002 Aug; 45 Suppl. 2: A51
51. Rossetti P, Costa E, Pampanelli S, et al. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime. Diabetes Care 2003; 26 (5): 1490-6
52. Witthaus E, Stewart J, Bradley C. Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with type 1 diabetes. Diabet Med 2001 Aug; 18 (8): 619-25
53. Bradley C. The Diabetes Treatment Satisfaction Questionnaire: DTSQ. Handbook of psychology and diabetes: a guide to psychological measurement in diabetes research and practice. Chur: Harwood Academic Publishers, 1994: 111-32
54. Bradley C. The Well-being Questionnaire. Handbook of psychology and diabetes: a guide to psychological measurement in diabetes research and practice. Chur: Harwood Academic Publishers, 1994: 89-109
55. Hamann A, Matthaei S, Rosak C, et al. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes. Diabetes Care 2003; 26 (6): 1738-44
56. Silvestre L, Bradley C, Witthans E, et al. Improved treatment satisfaction and perceived metabolic control with insulin glargine, regardless of whether injected before breakfast, dinner or bedtime in patients with type 1 diabetes [abstract]. Proceedings of the 63rd Annual Scientific Sessions of the American Diabetes Association; 2003 Jun 13-17; New Orleans, Louisiana
57. Dreyer M. Glycemic control with insulin glargine in patients with type 1 diabetes is maintained in long-term exposure [abstract]. Diabetes 2002 Jun; 51 Suppl. 2: A129
58. Garg SK, Izuora KE, Hisatomi ME, et al. Impact of insulin glargine on glycemic control and severe hypoglycemic episodes in adults with type 1 diabetes [abstract no. 1936-PO]. Proceedings of the 63rd Annual Scientific Sessions of the American Diabetes Association; 2003 Jun 13-17; New Orleans, Louisiana
59. Kelly JL, Hirsch IB, Trence DL. Rapid decrease in clinically significant hypoglycemia with insulin glargine [abstract]. Diabetes 2002 Jun; 51 Suppl. 2: A123
60. Armstrong DU, King AB. Basal insulin: continuous glucose monitoring reveals less over-night hypoglycemia with continuous subcutaneous insulin infusion than with glargine [abstract]. Diabetes 2002 Jun; 51 Suppl. 2: A92
61. Wolpert HA, Porter SH. Partial basal replacement with glargine reduces ketosis after interruption of continuous subcutaneous insulin infusion [abstract no. 548-P]. Diabetes 2002 Jun; 51 Suppl. 2: A136
62. Lepore G, Dodesini AR, Nosari I, et al. Both continuous subcutaneous insulin infusion and a multiple daily insulin injection regimen with glargine as basal insulin are equally better than traditional multiple daily insulin injection treatment [letter]. Diabetes Care 2003 Apr; 26 (4): 1321-2
63. Bode W, Hirsch IB, Hu P, et al. Type 1 diabetes patients can temporarily switch from continuous subcutaneous insulin infusion with insulin aspart to basal bolus therapy with insulin aspart and insulin glargine [abstract no. 438-P]. Proceedings of the 63rd Annual Scientific Sessions of the American Diabetes Association; 2003 Jun 13-17; New Orleans, Louisiana
64. Bode B, Schleusener D, Strange P, et al. Switch from continuous subcutaneous insulin (CSII) with insulin lispro [Humalog®] to multiple daily injections (MDI) with insulin glargine and insulin lispro [abstract]. Proceedings of the 63rd Annual Scientific Sessions of the American Diabetes Association ; 2003 Jun 13-17; New Orleans, Louisiana
65. Schober E, Schoenle E, Van Dyk J, et al. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2002 Apr; 15 (4): 369-76
66. Murphy NP, Keane SM, Ong KK, et al. Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care 2003 Mar; 26 (3): 799-804
67. Dunger DB, Edge JA, Skvor J. Insulin glargine provides long-term effective glycemic control in children and adolescents with type 1 diabetes [abstract]. Diabetes 2002 Jun; 51 Suppl. 2: A426
68. Herwig J, Scholl-Schilling G, Böhles H. Experience with insulin glargine in children, juveniles, and adolescents with type 1 diabetes: a prospective study [abstract no. 8712]. Diabetologia 2002 Aug; 45 Suppl. 2: A281-2
69. Dixon BF, Chase HP, Fiallo-Scharer RH, et al. The addition of insulin glargine to lower hypoglycemic events and AlC levels in children and adolescents with type 1 diabetes [abstract no. 1736-P]. Proceedings of the 63rd Annual Scientific Sessions of the American Diabetes Association; 2003 Jun 13-17; New Orleans, Louisiana
70. Pearson J, Chase HP, Wightman C, et al. Reduction of severe hypoglycemic episodes in children and adolescents with type 1 diabetes using insulin-glargine therapy [abstract]. Diabetes 2002 Jun; 51 Suppl. 2: A425
71. Kordonouri O, Deiss D, Hopfen-Mueller W, et al. Treatment with insulin glargine (Lantus®) reduces asymptomatic nightly hypoglycemia detected by continuous subcutaneous glucose monitoring in children and adolescents with type 1 diabetes [abstract]. Diabetes 2002 Jun; 51 Suppl. 2: 427
72. Barnett AH. Basal insulin: answers from analogues? Pract Diabetes Int 2002; 19 (7): 213-6
73. Siegmund T, Born T, Weber S, et al. Basal insulin therapy in type 2 diabetes: a prospective 18 month comparison of insulin glargine and NPH insulin in patients with a multiple injection regimen [abstract no. 1976-PO]. Proceedings of the 63rd Annual Scientific Sessions of the American Diabetes Association; 2003 13-16 Jun; New Orleans, Louisiana
74. Fonseca V, Bell D, Mecca T. Less symptomatic hypoglycemia with bedtime insulin glargine (Lantus) compared to bedtime NPH insulin in patients with type 2 diabetes [abstract no. 449-P]. Diabetes 2001; 50 Suppl. 2: 112-3
75. Fritsche A, Schweitzer MA, Häring H-U, et al. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes; a randomized, controlled trial. Ann Intern Med 2003; 138: 952-9
76. Massi Benedetti M, Humburg E, Dressler A, et al. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res 2003 Mar; 35 (3): 189-96
77. Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in type 2 diabetic patients. HOE 901/2004 Study Investigators Group. Diabetic Med 2003; 20: 545-51
78. Raskin P, Park G, Zimmermann J. The effect of HOE 901 on glycaemic control in type 2 diabetes [abstract]. Diabetes 1998; 47 Suppl. 1: A103
79. Riddle M, Rosenstock J. Treatment to target in type 2 diabetes: successful glycemic control with less nocturnal hypoglycaemia with insulin glargine versus NPH insulin added to oral therapy [abstract no. 150]. Diabetologia 2002 Aug; 45 Suppl. 2: A52
80. Rosenstock J, Schwartz SL, Clark Jr CM, et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001; 24: 631-6
81. Yki-Järvinen H, Dressler A, Ziemen M, et al. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000; 23: 1130-6
82. Witthaus E, Stewart J, Bradley C. Improved psychological outcomes after initiation of insulin treatment in patients with type II diabetes [abstract no. 787]. Diabetologia 2000; 43 Suppl. 1: A205
83. Standl E, Maxeiner S, Schweitzer MA, et al. Morning versus bedtime insulin glargine in combination with glimepiride: no differences in incidence of nocturnal hypoglycemia in patients with type 2 diabetes [abstract]. Proceedings of the 63rd Annual Scientific Sessions of the American Diabetes Association; 2003 Jun 13-17; New Orleans, Louisiana
84. Rosenstock J, Benedetti MM, Häring H-U, et al. Confirmed lower risk of hypoglycemia with insulin glargine versus NPH insulin: a meta-analysis of 2304 patients with type 2 diabetes [abstract]. Proceedings of the 63rd Annual Scientific Sessions of the American Diabetes Association ; 2003 Jun 13-17; New Orleans, Louisiana
85. Yki-Järvinen H, Häring H-U, Johnson E, et al. The relationship between glycemic control and hypoglycemia using insulin glargine versus NPH insulin: a meta-regression analysis in type 2 diabetes [abstract]. Proceedings of the 63rd Annual Scientific Sessions of the American Diabetes Association; 2003 Jun 13-17; New Orleans, Louisiana
86. Karacovsky-Bielesc G, Hirtz R. Glycemic control with insulin glargine in patients with type 2 diabetes is safely maintained in long-term exposure [abstract no. 1191-P]. Diabetes 2002 Jun; 51 Suppl. 2: A293
87. Fritsche A, Häring H-U, Togel E, et al. Treat-to-target with add-on basal insulin: can insulin glargine reduce the barrier to target attainment? [abstract]. Proceedings of the 63rd Annual Scientific Sessions of the American Diabetes Association; 2003 Jun 13-17; New Orleans, Louisiana
88. Fischer JS, Dirani RG, Schwartz SL, et al. Impact of use of insulin, glargine, on Hbg Alc and BMI in a speciality (endocrine) practice population [abstract no. 393-P]. Diabetes 2002 Jun; 51 Suppl. 2: A97
89. Schreiber S, Russmann A. Improved metabolic control in patients with type 1 and type 2 diabetes following the initiation/switching to insulin glargine in clinical practice [abstract no. 465-P]. Diabetes 2002 Jun; 51 Suppl. 2: A114-5
90. Pscherer S, Schreyer-Zell G, Gottsmann M. Experience with insulin glargine in patients with end-stage renal disease [abstract no. 216-OR]. Diabetes 2002 Jun; 51 Suppl. 2: A53
91. Schreiber SA, Russmann A. Long-term administration of insulin glargine (Lantus®): metabolic and weight benefits in patients with type 2 diabetes in clinical practice [abstract]. Proceedings of the 63rd Annual Scientific Sessions of the American Diabetes Association; 2003 Jun 13-17; New Orleans, Louisiana
92. Schreiber SA, Russmann A. Improved metabolic control with a favorable weight profile in patients with type 2 diabetes treated with insulin glargine in clinical practice [abstract no. 464-P]. Diabetes 2002 Jun; 51 Suppl. 2: A114
93. Stryjek-Kaminska D, Plininger I, Jaursch-Hancke C. Combined insulin glargine and metformin therapy for obese patients with type 2 diabetes mellitus [abstract no. 2531-P]. Diabetes 2002 Jun; 51 Suppl. 2: A423-4
94. Schiel R, Schweitzer MA, Müller U. Patients with type 2 diabetes on long-term insulin therapy can be switched to a single dose of insulin glargine plus oral hypoglycemic agents [abstract]. Proceedings of the 63rd Annual Scientific Sessions of the American Diabetes Association; 2003 Jun 13-17; New Orleans, Louisiana
95. Marbury T, Schwartz S, Rosenberg MA, et al. Evaluation of the safety, efficacy and tolerability of insulin glargine in subjects with impaired fasting glucose, impaired glucose tolerance or new-onset type 2 diabetes [abstract]. Proceedings of the 63rd Annual Scientific Sessions of the American Diabetes Association ; 2003 Jun 13-17; New Orleans, Louisiana
96. Brange J, Volund A. Insulin analogs with improved pharmacokinetic profiles. Adv Drug Deliv Rev 1999; 35: 307-35
97. Forjanic-Klapproth J, Home P. Progression of retinopathy with insulin glargine or NPH insulin: a multi-trial analysis [abstract no. 1103]. Diabetologia 2001; 44 Suppl. 1: A287
98. Berkowitz K. Lantus? Or Lente? Am J Nuts 2002 Aug; 102 (8): 55
99. Harmel AL, Somma L. Not all long-acting insulins are the same [letter]. Diabetes Care 2002 Sep; 25 (9): 1666-7
100. Phillips W, Lando H. Insulin confusion: an observation [letter]. Diabetes Care 2002 Jun; 25 (6): 1103-4
101. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Eng J Med 2000; 342: 381-9
102. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Eng J Med 1993; 329: 977-86
103. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-12
104. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53
105. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65
106. Lawson ML, Gerstein HC, Tsui E, et al. Effect of intensive therapy on early macrovascular disease in young individuals with type 1 diabetes: a systematic review and meta-analysis. Diabetes Care 1999; 22 Suppl. 2: B35-9
107. Lindholm A. New insulins in the treatment of diabetes mellitus. Best Pract Res Clin Gastroenterol 2002 Jun; 16 (3): 475-92
108. DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA 2003 May 7; 289 (17): 2254-64
109. Lindström T, Olsson PO, Arnqvist HJ. The use of human ultralente is limited by great intraindividual variability in overnight plasma insulin profiles. Scand J Clin Lab Invest 2000; 60: 341-7
110. Aventis. Lantus® receives European approval for flexible administration: also receives positive opinion for pediatric use from the European Committee for Proprietary Medicinal Products. Media Rel Available from URL: Http://www.emea.eu.int [Accessed 2003 Jul 16]
111. Aventis (US). Lantus® (insulin glargine [rDNA origin] injection) receives FDA approval for flexible administration [online]. Available from URL: http://www.aventis.com [Accessed 2003 May 27]